PMID- 29573228
OWN - NLM
STAT- MEDLINE
DCOM- 20191017
LR  - 20240314
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 7
IP  - 5
DP  - 2018 May
TI  - A prospective study of soluble receptor for advanced glycation end products and 
      adipokines in association with pancreatic cancer in postmenopausal women.
PG  - 2180-2191
LID - 10.1002/cam4.1426 [doi]
AB  - Advanced glycation end products (AGEs) dysregulate adipokines and induce 
      inflammation by binding to their adipocyte receptor (RAGE). Soluble RAGE (sRAGE) 
      prevents AGEs/RAGE signaling. We performed a nested case-control study of the 
      association between sRAGE, adipokines, and incident pancreatic cancer risk in the 
      prospective Women's Health Initiative Study. We individually matched controls 
      (n = 802) to cases (n = 472) on age, race, and blood draw date. We evaluated 
      serum concentrations of sRAGE, adiponectin, leptin, monocyte chemotactic protein 
      1 (MCP1), and plasminogen activator inhibitor-1 (PAI1) using immunoassay. We used 
      conditional logistic regression model to estimate adjusted odds ratios (aORs) and 
      95% confidence intervals (CIs) for pancreatic cancer over biomarker quartiles 
      (Q1-Q4). We used principal component analysis to create two composite biomarkers 
      and performed a confirmatory factor analysis to examine the association between 
      composite biomarker scores (CBS) and pancreatic cancer risk. Baseline serum sRAGE 
      concentrations were inversely associated with pancreatic cancer risk (aOR(Q4 vs. 
      Q1 ) = 0.70, 95% CI: 0.50-0.99). High MCP1 (aOR (Q4 vs. Q1 ) = 2.55, 95% CI: 
      1.41-4.61) and the higher CBS including MCP1, PAI1, and leptin (aOR(Q4 vs. Q1 ) 
      = 1.82, 95% CI = 1.04-3.18) were also associated with increased pancreatic cancer 
      risk among women with BMI <25 kg/m(2) (P values for interaction <0.05). We found 
      an inverse association between prediagnostic sRAGE concentrations and risk of 
      incident pancreatic cancer in postmenopausal women. A proinflammatory CBS was 
      associated with increased risk only in women with normal BMI. MCP1 was not 
      modulated by sRAGE.
CI  - (c) 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - White, Donna L
AU  - White DL
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
AD  - Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
AD  - Texas Medical Center Digestive Disease Center, Houston, Texas.
AD  - Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas.
AD  - Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
FAU - Hoogeveen, Ron C
AU  - Hoogeveen RC
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
FAU - Chen, Liang
AU  - Chen L
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
AD  - Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
FAU - Richardson, Peter
AU  - Richardson P
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
AD  - Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
FAU - Ravishankar, Milan
AU  - Ravishankar M
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
FAU - Shah, Preksha
AU  - Shah P
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
AD  - Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
FAU - Tinker, Lesley
AU  - Tinker L
AD  - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 
      Seattle, Washington.
FAU - Rohan, Thomas
AU  - Rohan T
AD  - Albert Einstein College of Medicine, Bronx, New York.
FAU - Whitsel, Eric A
AU  - Whitsel EA
AD  - Gillings School of Global Public Health, University of North Carolina at Chapel 
      Hill, Chapel Hill, North Carolina.
FAU - El-Serag, Hashem B
AU  - El-Serag HB
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
AD  - Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
AD  - Texas Medical Center Digestive Disease Center, Houston, Texas.
AD  - Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas.
FAU - Jiao, Li
AU  - Jiao L
AUID- ORCID: 0000-0002-0237-0262
AD  - Department of Medicine, Baylor College of Medicine, Houston, Texas.
AD  - Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
AD  - Texas Medical Center Digestive Disease Center, Houston, Texas.
AD  - Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas.
AD  - Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. 
      DeBakey VA Medical Center, Houston, Texas.
LA  - eng
GR  - R01 CA172880/CA/NCI NIH HHS/United States
GR  - I01 CX001430/CX/CSRD VA/United States
GR  - P30 DK056338/DK/NIDDK NIH HHS/United States
GR  - P30 DK020541/DK/NIDDK NIH HHS/United States
GR  - P30 CA022453/CA/NCI NIH HHS/United States
GR  - N01WH22110/WH/WHI NIH HHS/United States
GR  - N01WH24152/WH/WHI NIH HHS/United States
GR  - N01WH32100/WH/WHI NIH HHS/United States
GR  - N01WH32105/HL/NHLBI NIH HHS/United States
GR  - N01WH32108/WH/WHI NIH HHS/United States
GR  - N01WH32111/WH/WHI NIH HHS/United States
GR  - N01WH32115/WH/WHI NIH HHS/United States
GR  - N01WH32118/HL/NHLBI NIH HHS/United States
GR  - N01WH32119/WH/WHI NIH HHS/United States
GR  - N01WH32122/WH/WHI NIH HHS/United States
GR  - N01WH42107/HL/NHLBI NIH HHS/United States
GR  - N01WH42129/WH/WHI NIH HHS/United States
GR  - N01WH44221/WH/WHI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20180323
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (AGER protein, human)
RN  - 0 (Adipokines)
RN  - 0 (Adiponectin)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Leptin)
RN  - 0 (Plasminogen Inactivators)
RN  - 0 (Receptor for Advanced Glycation End Products)
SB  - IM
MH  - Adipokines/*blood
MH  - Adiponectin/blood
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Case-Control Studies
MH  - Chemokine CCL2/blood
MH  - Female
MH  - Humans
MH  - Leptin/blood
MH  - Middle Aged
MH  - Pancreatic Neoplasms/*blood/*epidemiology/pathology
MH  - Plasminogen Inactivators/blood
MH  - Postmenopause/blood
MH  - Principal Component Analysis
MH  - Prospective Studies
MH  - Receptor for Advanced Glycation End Products/*blood
MH  - Risk
PMC - PMC5943487
OTO - NOTNLM
OT  - Biomarker
OT  - CCL2
OT  - body weight
OT  - composite biomarker
OT  - pancreatic cancer
OT  - prospective
OT  - sRAGE
EDAT- 2018/03/25 06:00
MHDA- 2019/10/18 06:00
PMCR- 2018/03/23
CRDT- 2018/03/25 06:00
PHST- 2018/01/09 00:00 [received]
PHST- 2018/01/30 00:00 [revised]
PHST- 2018/02/09 00:00 [accepted]
PHST- 2018/03/25 06:00 [pubmed]
PHST- 2019/10/18 06:00 [medline]
PHST- 2018/03/25 06:00 [entrez]
PHST- 2018/03/23 00:00 [pmc-release]
AID - CAM41426 [pii]
AID - 10.1002/cam4.1426 [doi]
PST - ppublish
SO  - Cancer Med. 2018 May;7(5):2180-2191. doi: 10.1002/cam4.1426. Epub 2018 Mar 23.